Please use this identifier to cite or link to this item:
Title: Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein
Authors: Ridker, Paul M.
Fonseca, Francisco A. H. [UNIFESP]
Genest, Jacques
Gotto, Antonio M.
Kastelein, John J. P.
Khurmi, Nardev S.
Koenig, Wolfgang
Libby, Peter
Lorenzatti, Alberto J.
Nordestgaard, Borge G.
Shepherd, James
Willerson, James T.
Glynn, Robert J.
Grp, JTS
Brigham & Womens Hosp
Universidade Federal de São Paulo (UNIFESP)
McGill Univ
Cornell Univ
Univ Amsterdam
Astra Zeneca
Univ Ulm
Hosp Cordoba
Herlev Univ Hosp
Univ Glasgow
St Lukes Episcopal Hosp
Issue Date: 1-Dec-2007
Publisher: Elsevier B.V.
Citation: American Journal of Cardiology. Bridgewater: Excerpta Medica Inc-Elsevier B.V., v. 100, n. 11, p. 1659-1664, 2007.
Abstract: The Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) is a randomized, double-blind, placebo-controlled primary prevention trial of statin therapy among persons with average to low levels of low-density lipoprotein (LDL) cholesterol who are at increased cardiovascular risk due to elevated plasma concentrations of the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP). A total of 17,802 persons with LDL cholesterol <130 mg/dl (3.36 mmol/L) and hs-CRP >= 2 mg/L were recruited from 26 countries and randomly allocated to 20 mg/day rosuvastatin or placebo. in contrast to previous studies of statin therapy in primary prevention, JUPITER is evaluating a group with modest plasma concentrations of LDL cholesterol (median 108 mg/dl, interquartile range 94 to 119). Further, the trial includes 6,801 women (38.2%) and 5,577 participants with metabolic syndrome (32.1%). Thus, in addition to broadening our understanding of statin therapy and inflammation, the JUPITER trial will provide important and clinically relevant information on primary prevention among patients who do not currently qualify for lipid-lowering therapy. in conclusion, as 20 mg of rosuvastatin can reduce LDL cholesterol by up to 50%, JUPITER will also provide crucial safety data for several thousand patients who should achieve LDL cholesterol levels <50 mg/dl on a long-term basis. (c) 2007 Elsevier Inc. All rights reserved.
ISSN: 0002-9149
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.